Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

LGVN Longeveron Inc

1,66

0,06 (3,75%)

Nach Börsenschluss

Zuletzt aktualisiert: 23:56:22

Verzögert um 15 Minuten

Annual Report to Security Holders (ars)

This regulatory filing also includes additional resources:
fars0423_longeveron.pdf

Longeveron (NASDAQ:LGVN)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Click Here for more Longeveron Charts.

Longeveron (NASDAQ:LGVN)
Historical Stock Chart
Von Dez 2023 bis Dez 2024

Click Here for more Longeveron Charts.

News Longeveron Inc.

Longeveron to Present at Biotech Showcase 2025
Mittwoch 18 Dezember 2024 (2 Tage vor) • GlobeNewswire Inc.

Form 8-K - Current report
Dienstag 12 November 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Dienstag 12 November 2024 (1 Monat vor) • Edgar (US Regulatory)

Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
Dienstag 12 November 2024 (1 Monat vor) • GlobeNewswire Inc.

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)
Montag 11 November 2024 (1 Monat vor) • GlobeNewswire Inc.

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
Montag 4 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
Dienstag 29 Oktober 2024 (2 Monate vor) • GlobeNewswire Inc.

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
Sonntag 27 Oktober 2024 (2 Monate vor) • GlobeNewswire Inc.

Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
Montag 14 Oktober 2024 (2 Monate vor) • GlobeNewswire Inc.

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
Mittwoch 9 Oktober 2024 (2 Monate vor) • GlobeNewswire Inc.

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
Montag 7 Oktober 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 4 Oktober 2024 (3 Monate vor) • Edgar (US Regulatory)

Weitere Longeveron Inc. News-Artikel

Financial Select Sector

Euro vs US Dollar

Deutsche Lufthansa

Deutsche Telekom

Deutsche Telekom (QX)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen